Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria.

Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disease of hematopoietic stem cells that is associated with hemolysis, marrow failure, and thrombophilia. PNH has been considered a monogenic disease that results from somatic mutations in the gene encoding PIGA, which is required for biosynthesis of glycosylphosphatidylinisotol-anchored (GPI-anchored) proteins. The loss of certain GPI-anchored proteins is hypothesized to provide the mutant clone with an extrinsic growth advantage, but some features of PNH argue that there are intrinsic drivers of clonal expansion. Here, we performed whole-exome sequencing of paired PNH+ and PNH- fractions on samples taken from 12 patients as well as targeted deep sequencing of an additional 36 PNH patients. We identified additional somatic mutations that resulted in a complex hierarchical clonal architecture, similar to that observed in myeloid neoplasms. In addition to mutations in PIGA, mutations were found in genes known to be involved in myeloid neoplasm pathogenesis, including TET2, SUZ12, U2AF1, and JAK2. Clonal analysis indicated that these additional mutations arose either as a subclone within the PIGA-mutant population, or prior to PIGA mutation. Together, our data indicate that in addition to PIGA mutations, accessory genetic events are frequent in PNH, suggesting a stepwise clonal evolution derived from a singular stem cell clone.

[1]  Li Wang,et al.  SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis , 2014, Tumor Biology.

[2]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[3]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[4]  P. Robinson,et al.  A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. , 2013, Blood.

[5]  L. Gorunova,et al.  RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12) , 2013, Genes, chromosomes & cancer.

[6]  S. Miyano,et al.  Somatic SETBP1 mutations in myeloid malignancies , 2013, Nature Genetics.

[7]  B. Bjerkehagen,et al.  Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22‐translocation , 2013, Genes, chromosomes & cancer.

[8]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[9]  C. Giachelli,et al.  Mice lacking the sodium-dependent phosphate import protein, PiT1 (SLC20A1), have a severe defect in terminal erythroid differentiation and early B cell development. , 2013, Experimental hematology.

[10]  Sai Zhang,et al.  FoxQ1 Promotes Glioma Cells Proliferation and Migration by Regulating NRXN3 Expression , 2013, PloS one.

[11]  S. Miyano,et al.  Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies , 2013, Leukemia.

[12]  H. Shimada,et al.  Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ–TIF2 fusion , 2013, International Journal of Hematology.

[13]  O. Abdel-Wahab,et al.  The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics , 2013, Leukemia.

[14]  Ji-Young Kim,et al.  KDM3B Is the H3K9 Demethylase Involved in Transcriptional Activation of lmo2 in Leukemia , 2012, Molecular and Cellular Biology.

[15]  J. Melo,et al.  BCR‐ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia , 2012, British journal of haematology.

[16]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[17]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[18]  R. Scolyer,et al.  Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases , 2012, Modern Pathology.

[19]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[20]  K. Moore,et al.  The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques , 2012 .

[21]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[22]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[23]  C. O'keefe,et al.  Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria , 2010, Leukemia.

[24]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[25]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[26]  Allen D. Delaney,et al.  High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy‐neutral loss of heterozygosity and copy number alterations that target single genes , 2010, Genes, chromosomes & cancer.

[27]  Ola Larsson,et al.  The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[28]  M. McDevitt,et al.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Hume,et al.  Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1. , 2009, Genomics.

[30]  C. O'keefe,et al.  Application of array‐based whole genome scanning technologies as a cytogenetic tool in haematological malignancies , 2009, British journal of haematology.

[31]  P. Varlet,et al.  Gene expression profiling provides insights into the pathways involved in solid pseudopapillary neoplasm of the pancreas , 2009, The Journal of pathology.

[32]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[33]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[34]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[35]  R. Brodsky Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. , 2008, Hematology. American Society of Hematology. Education Program.

[36]  Ken Kurokawa,et al.  Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). , 2006, Blood.

[37]  N. Young,et al.  Current concepts in the pathophysiology and treatment of aplastic anemia. , 2006, Blood.

[38]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[39]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[40]  H. Arakawa,et al.  Netrin-1 and its receptors in tumorigenesis , 2004, Nature Reviews Cancer.

[41]  D. Bredesen,et al.  Netrin-1 controls colorectal tumorigenesis by regulating apoptosis , 2004, Nature.

[42]  R. Bresalier,et al.  Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[43]  J. Tooze,et al.  N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. , 2000, Blood.

[44]  L Luzzatto,et al.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Morgan,et al.  Both paroxysmal nocturnal hemoglobinuria (PNH) type II cells and PNH type III cells can arise from different point mutations involving the same codon of the PIG-A gene. , 1997, Blood.

[46]  N. Young,et al.  Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. , 1997, Blood.

[47]  L. Luzzatto,et al.  Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria , 1994, The Lancet.

[48]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[49]  T. Huizinga,et al.  [Paroxysmal nocturnal hemoglobinuria]. , 1992, Nederlands tijdschrift voor geneeskunde.